Spots Global Cancer Trial Database for Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma
Official Title: Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma
Study ID: NCT04393220
Study Description
Brief Summary: The aie of this clinical study is the safety and efficacy of combination therapy for HCC patients.
Detailed Description: Activation of anti-tumor immune response using programmed death receptor-1 (PD-1)blockade showed benefit only in a fraction of hepatocellular carcinoma (HCC) patients. Specific blockade of vascular endothelial receptor 2 (VEGFR-2) using a murine antibody significantly delayed primary tumor growth but failed to prolong survival. Combining PD-1 blockade with antiangiogenesis has shown promise in substantially increasing the fraction of HCC patients who respond to treatment in vitro. Based on these clinical data, we are aimed to investigation the safety and efficacy of combination therapy for HCC patients.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Fuda Cnacer Hospital, Guangzhou, Guangdong, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
